Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Randomized, doublE-blind, Placebo-controlled, Prospective, Pharmacological interVention Study In Participants With Long COVID-19 Syndrome: REVIVE-TOGETHER Trial

NCT06128967 is registered in ClinicalTrials.gov with Cardresearch as lead sponsor.

NCT NCT06128967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06128967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Randomized, doublE-blind, Placebo-controlled, Prospective, Pharmacological interVention Study In Participants With Long COVID-19 Syndrome: REVIVE-TOGETHER Trial
Lead sponsor
Cardresearch
Phase
Phase 3
Overall status
Completed
Start date
October 18, 2023
Completion date
August 1, 2025
Enrollment
399 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic fatigue syndrome, long covid-19 syndrome